DRUG DEVELOPMENT TOPS FDA STRATEGIC ACTION PLAN

Drug Industry Daily
KEYWORDS FDA / Guidances
A A

The cost of bringing a new drug to market -- estimated to be between $800 million and $1.7 billion -- is a major barrier to firms considering investing in innovative higher-risk drugs or therapies for diseases that are uncommon or that predominantly afflict the poor, according to a new FDA report.

To View This Article:

Login

Subscribe To Drug Industry Daily